Welcome to our dedicated page for ACHIEVE LIFE SCIENCES SEC filings (Ticker: ACHV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Achieve Life Sciences SEC filings document current reports on operating results, cytisinicline development updates, governance matters, material agreements, and capital-structure disclosures. Recent Form 8-K filings include furnished financial-results releases and business updates tied to the company’s late-stage specialty pharmaceutical focus on cytisinicline for nicotine dependence.
The filing record also covers executive and board changes, compensatory arrangements, consulting and separation agreements, shareholder voting matters, security-structure disclosures, and clinical or regulatory disclosures related to the cytisinicline program. These filings provide formal records of the company’s corporate events, financial-condition updates, and governance actions as a public biotechnology issuer.
Achieve Life Sciences, Inc. (Nasdaq: ACHV) has filed a preliminary prospectus supplement (Form 424B5) for a public offering of (i) shares of common stock and accompanying five-year common warrants, or (ii) pre-funded warrants (exercise price $0.001) plus the same warrants, at the purchaser’s election. Exact share counts, warrant coverage and pricing are still blank in the preliminary document. Each unit is immediately separable; however, neither the pre-funded nor the common warrants will be listed on Nasdaq, limiting their liquidity. The company has granted underwriters Citizens Capital Markets and Raymond James a 30-day option to purchase additional shares and/or warrants.
Achieve qualifies as a smaller reporting company and intends to use reduced disclosure requirements. Its common stock last traded at $3.80 on 25 June 2025. Investors are urged to review the extensive risk factors beginning on page S-8.
Strategic and clinical updates disclosed in the filing:
- NDA submission (26 June 2025): Cytisinicline New Drug Application for adult smoking cessation filed with the FDA, supported by the Phase 3 ORCA-2 and ORCA-3 trials and long-term safety data from ORCA-OL.
- Breakthrough Therapy Designation: Previously received for a future vaping-cessation indication following a successful end-of-Phase 2 meeting with the FDA.
- Commercial readiness: Omnicom Group selected as strategic innovation partner and agency of record to prepare for a potential U.S. launch if FDA approves cytisinicline.
The transaction, once priced, is expected to provide fresh capital for regulatory, pre-launch and general corporate purposes but will dilute existing shareholders. No earnings, revenue or use-of-proceeds detail beyond standard language is provided in this preliminary filing.